Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted RNA sequencing with touch imprint cytology samples for non-small cell lung cancer patients.

Thoracic cancer - 1 Jul 2020

Seto Katsutoshi, Masago Katsuhiro, Fujita Shiro, Haneda Masataka, Horio Yoshitsugu, Hida Toyoaki, Kuroda Hiroaki, Hosoda Waki, Okubo Ken-Ichi

Abstract excerpt

BACKGROUND: RNA-based sequencing is considered ideal for detecting pathogenic fusion-genes compared to DNA-based assays and provides valuable information about the relative expression of driver genes. However, RNA from formalin-fixed paraffin-embedded tissue has issues with both quantity and quality, making RNA-based sequencing difficult in clinical practice. Analyzing stamp-derived RNA with next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Carcinoma, Squamous Cell

Share to Cytodiagnosis

Share to Cytological Techniques

Share to Lung Neoplasms

Share to Sequence Analysis, RNA

Source

Open in PubMed Open full text

Identifiers

PMID: 32372482
DOI: 10.1111/1759-7714.13460
PMCID: PMC7327906

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted RNA sequencing with touch imprint cytology samples for non-small cell lung cancer patients.PMID 32372482Read ↗

Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors.Semantic proximity Read ↗

Simultaneous detection of single-nucleotide variant, deletion/insertion, and fusion in lung and thyroid carcinoma using cytology specimen and an RNA-based next-generation sequencing assay.Semantic proximity Read ↗

Impact and Reproducibility of In-House Targeted Next-Generation Sequencing Biomarker Testing in Non–Small-Cell Lung CancerSemantic proximity Read ↗

Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.Semantic proximity Read ↗

Clinical Validation of a Targeted RNA-Sequencing Assay for Driver Gene Alteration Detection in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.Semantic proximity Read ↗

Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in NSCLCSemantic proximity Read ↗

Tumor molecular profiling of NSCLC patients using next generation sequencing.Semantic proximity Read ↗

Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer.Semantic proximity Read ↗

Integrating the Idylla™ System Alongside a Real-Time Polymerase Chain Reaction and Next-Generation Sequencing for Investigating Gene Fusions in Pleural Effusions from Non-Small-Cell Lung Cancer Patients: A Pilot Study.Semantic proximity Read ↗

Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.Semantic proximity Read ↗

Plasma biopsy by Tag-sequencing: an acceptable alternative to tumor tissue profiling in non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.